1.
A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6‐month intervention
by KAJANDER, K.
Alimentary pharmacology & therapeutics, 2005-09, Vol.22 (5), p.387-394
2.
CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn’s disease
by Heliö, T
Gut, 2003-04, Vol.52 (4), p.558-562
3.
Letter: risk factor and mortality of peptic ulcer disease – authors′ reply
by Malmi, H.
Alimentary pharmacology & therapeutics, 2016-08, Vol.44 (4), p.425-425
4.
Debulking or biopsy of malignant glioma in elderly people - a randomised study
by VUORINEN, V
Acta neurochirurgica, 2003, Vol.145 (1), p.5-10
5.
Trait Components Provide Tools to Dissect the Genetic Susceptibility of Migraine
by Anttila, V
American journal of human genetics, 2006, Vol.79 (1), p.85-99
6.
Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis
by Andersen, O
Journal of neurology, neurosurgery and psychiatry, 2004-05, Vol.75 (5), p.706-710
7.
Gastrointestinal complaints among subjects with depressive symptoms in the general population
by HILLILÄ, M. T.
Alimentary pharmacology & therapeutics, 2008-09, Vol.28 (5), p.648-654
8.
Incidence and complications of peptic ulcer disease requiring hospitalisation have markedly decreased in Finland
by Malmi, H.
Alimentary pharmacology & therapeutics, 2014-03, Vol.39 (5), p.496-506
9.
FRI0061 The Concomitance of Inflammatory Bowel Disease with Incident Rheumatoid Arthritis and Ankylosing Spondylitis in Finland
by Puolakka, K
Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.403-404
10.
Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection
by Alsiö, Å
European journal of clinical microbiology & infectious diseases, 2011-11-24, Vol.31 (7), p.1631-1635
11.
Increased short‐ and long‐term mortality in 8146 hospitalised peptic ulcer patients
by Malmi, H.
Alimentary pharmacology & therapeutics, 2016-08, Vol.44 (3), p.234-245
12.
Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings
by SIPPONEN, T.
Alimentary pharmacology & therapeutics, 2008-11, Vol.28 (10), p.1221-1229
13.
Migraine with Aura Is a Risk Factor for Cervical Artery Dissection: A Case-Control Study
by Artto, V
Cerebrovascular diseases (Basel, Switzerland), 2010-06, Vol.30 (1), p.36-40
14.
Cerebrospinal fluid findings in multiple sclerosis patients before, during and after pregnancy
by Saraste, M
Journal of neurology, neurosurgery and psychiatry, 2006-10, Vol.77 (10), p.1195-1196
15.
Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non‐selected adult population
by Hillilä, M. T.
Alimentary pharmacology & therapeutics, 2004-08, Vol.20 (3), p.339-345
16.
Immune activation in the small intestine in patients with rheumatoid arthritis
by Nissinen, R
Annals of the rheumatic diseases, 2004-10, Vol.63 (10), p.1327-1330
17.
Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis
by RAUTIAINEN, H.
Alimentary Pharmacology and Therapeutics, 2006-12, Vol.24 (11‐12), p.1545-1552
18.
Immunohistochemical study of neuroendocrine cells at the gastric cardia mucosa
by Voutilainen, M
Journal of clinical pathology, 2002-10, Vol.55 (10), p.767-769
19.
20.
In vitro acetaldehyde formation by human colonic bacteria
by Jokelainen, K
Gut, 1994-09, Vol.35 (9), p.1271-1274
